echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Clini Cancer Res: PD-L1 expression is associated with the prognosis of new complementary chemotherapy for triple-negative breast cancer.

    Clini Cancer Res: PD-L1 expression is associated with the prognosis of new complementary chemotherapy for triple-negative breast cancer.

    • Last Update: 2020-07-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    !---- background: In the Keynote 522 trial in the context of metastasis, three-negative breast cancer (TNBC) patients benefited from PD-1 axis immunotherapy.therefore, the study used a quantitative immunohistometal method to detect the expression of PD-L1 in tumor cells and immune cells to assess the correlation between PD-L1 expression and the benefits of combined chemotherapy using new auxiliary defertilated in TNBC patients.method: Obtaining pre-treatment acupuncture biopsy tissue (n-69) in patients participating in Phase II clinical trials (NCT02489448), and 45 patients were finally analyzed according to the quality of the tissues (qCR?18, non-pCR-27).results: The expression of PD-L1 in pCR patients increased significantly compared to those with non-pCR.in pCR and non-pCR cases, there was no difference in the number of CD68-positive cells in tumor or interstitial chambers: PD-L1 was expressed in tumor cells, interstitial immune cells, and co-located with CD68-positive cells, associated with high pCR rates in TNBC patients with dalsating monotomachecklista chemotherapy therapy..
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.